Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The radiopharmaceutical-focused company faced headwinds from increased competition in the PSMA PET landscape, impacting its flagship product PYLARIFY.
Lantheus reported Q2 adjusted earnings of $1.57 per share, falling short of analysts' expectations of $1.67. Revenue for the quarter came in at $378 million, missing the consensus estimate of $389.1 million and representing a 4.1% year-over-year decline. The company's PYLARIFY sales, a key growth driver, decreased by 8.3% to $250.6 million due to heightened competition in the PSMA PET market.
In response to the challenging environment, Lantheus significantly lowered its full-year 2025 guidance. The company now expects revenue between $1.475 billion and $1.51 billion, down from the previous range of $1.55 billion to $1.59 billion. Adjusted earnings per share guidance was also reduced to $5.50-$5.70 from $6.60-$6.70. This substantial downward revision in outlook further contributed to the sharp decline in the stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.